12 JulyGeraldine MacGibbon Senior Therapeutic Group Manager PHARMAC PO Box

First Page		Document Content
Date: 2016-07-11 21:31:12 Clinical medicine Breakthrough therapy Medicine Antineoplastic drugs Pharmacology Monoclonal antibodies Bristol-Myers Squibb Nivolumab Melanoma Programmed cell death protein 1 Pembrolizumab Raltegravir		12 JulyGeraldine MacGibbon Senior Therapeutic Group Manager PHARMAC PO Box Add to Reading List Source URL: www.nzma.org.nz Download Document from Source Website File Size: 204,40 KB Share Document on Facebook

	CONTACT: Media: Charlene McGrady, extMDS Pharma Services Scientist to Discuss Development of Biosimilar Monoclonal Antibodies at EGA Symposium DocID: 1vhgc - View Document
	ABIRISK ABIRISK Project Officially Started A growing number of medicines are based on biological molecules such as proteins and monoclonal antibodies. These novel drugs have resulted in new, more effective treatments for DocID: 1v3WA - View Document
	Celartia Protocols Hybridoma Cell culture with Petaka-HOT (High Oxygen Turnover, orange port) Production of Monoclonal Antibodies Petaka-HOT allows culturing non adherent DocID: 1uTpm - View Document
	INTERNSHIP PROPOSAL Institute and Group: IBS group HIV and persistent human viruses Supervisor: Pascal Poignard Email: Research project title: Human monoclonal antibodies: a new therapeutic strategy DocID: 1uPEI - View Document
	Visterra Acquires Exclusive Patent License for Monoclonal Antibodies against Dengue Virus from MIT – Expands Company’s Therapeutic Pipeline for Infectious Diseases – Cambridge, MA – December 2, 2013 – Visterra, DocID: 1ujGa - View Document